Toll-like receptors (TLRs) play critical roles in host defense after recognition of conserved microbial- and host-derived components, and their dysregulation is a common feature of various
inflammation-associated
cancers, including
gastric cancer (GC). Despite the recent recognition that metabolic reprogramming is a hallmark of
cancer, the molecular effectors of altered metabolism during
tumorigenesis remain unclear. Here, using bioenergetics function assays on human GC cells, we reveal that
ligand-induced activation of TLR2, predominantly through TLR1/2 heterodimer, augments both oxidative phosphorylation (OXPHOS) and glycolysis, with a bias toward glycolytic activity. Notably,
DNA microarray-based expression profiling of human
cancer cells stimulated with TLR2
ligands demonstrated significant enrichment of gene-sets for oncogenic pathways previously implicated in metabolic regulation, including
reactive oxygen species (ROS), p53 and Myc. Moreover, the redox gene encoding the
manganese-dependent mitochondrial
enzyme,
superoxide dismutase (SOD)2, was strongly induced at the
mRNA and
protein levels by multiple signaling pathways downstream of TLR2, namely JAK-STAT3, JNK MAPK and NF-κB. Furthermore,
siRNA-mediated suppression of SOD2 ameliorated the TLR2-induced metabolic shift in human GC
cancer cells. Importantly, patient-derived tissue microarrays and bioinformatics interrogation of clinical datasets indicated that upregulated expression of TLR2 and SOD2 were significantly correlated in human GC, and the TLR2-SOD2 axis was associated with multiple clinical parameters of advanced stage disease, including distant
metastasis, microvascular invasion and stage, as well as poor survival. Collectively, our findings reveal a novel TLR2-SOD2 axis as a potential
biomarker for
therapy and prognosis in
cancer.